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Proteins Don’t Have a Social Life: Proteomics Past, Present and Future

Ruth McNally and Peter Glasner

Whilst genomics is used to celebrity, it is rare for proteomics to be centre stage. Here CESAGen shines the spotlight on proteomics, its history, its relationships with genomics, and its role in the New Biology.

Most people reading this will have never heard of proteomics.  It shares little of the notoriety of its close bio-molecular cousin, genomics. Coined in 1994, the “proteome” is the protein equivalent of the genome, and proteomics is the study of the proteome. Although for the first half of the 20th century proteins were hot contenders as the molecular basis of the gene, as we all know it was DNA that was granted that status. For the past 50 years proteins have been subordinated to DNA under Francis Crick’s Central Dogma of Molecular Genetics, according to which “DNA makes RNA makes protein”. In the biomolecular politics of the cell, DNA is the Master Molecule and gene incarnate, a status that underpinned one of the most arresting rationales for the Human Genome Project, namely that to know the genomic DNA sequences of living organisms is to have access to the “Book of Life”. 

But DNA pays a price for its elevated status. By association with the gene, manipulation of DNA, whether in microbes, plants or animals, is regarded as more than mere biomolecular engineering. Rather, it is viewed as tampering with life itself, arousing not just hopes but also consternation, controversy and conflict.  Talk of protein therapy, by contrast, is likely to trouble few. For most people, proteins are something they eat, and if they are body-builders, something they try to accumulate in the right places. Apart from this, proteins are unlikely to be the subject of heated conversations over dinner or feature in the broadcast media. Social activists don’t campaign against protein research; there is no Ethical Legal and Social Implications (ELSI) research initiative under the Human Proteome Project; and there is no ESRC Proteomics Network. In contrast with the DNA-gene, “proteins don’t have a social life”, and proteomics doesn’t seem to have issues on anything like the scale of genomics.   
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Proteomics, protein chemistry and protein physiology have a history that is intertwined with that of genomics and genetics. Telling the story of proteomics is like writing the backstage story to the genomics blockbuster, although in some respects protein research can claim to have been the forerunner of the research approach that genomics is said to typify. 

Protein researchers were the first to advocate the large-scale (or “omic”) cataloguing of an entire class of biomolecules, and were also early adopters of e-science, seeing the potential of information and communication technologies for disseminating protein data and analysis tools. In the late 1970s, prior to discussion of the Human Genome Project, N. Leigh Anderson and his father Norman undertook a pilot study for the Human Protein Index (HPI), a computerized database that would catalogue and compare all human proteins and be remotely accessible by researchers and clinicians via satellite. Indeed, in a leap of the imagination that prefigured systems biology, they envisaged the HPI as just part of a larger project that would characterize all the molecular constituents of living cells. Later, in the 1980s, in parallel with the compilation of genome sequence databases at EMBL and GenBank, the computerized protein sequence database Swiss-Prot was also being compiled; and the first life sciences server on the Web was ExPASy, the Expert Protein Analysis System, which made Swiss-Prot available on internet in 1993. 

The completion of the HGP was formally announced in 2003, and the availability of complete genomic DNA sequences is widely acknowledged to be an achievement of immense value as a research resource. However, the unexpectedly small number of human genes (then 45,000, now 22,000) in comparison to a conservative estimate of the number of proteins (1 million) made it abundantly clear that the proteome is neither wholly predictable from, nor reducible to, the DNA genome.  

Hailed as the “Next Big Thing”, the completion of the HGP was used both positively and negatively as a platform for the launch of HUPO and the Human Proteome Project; positively in the sense that the HGP was portrayed as the model for a new era of research in the biosciences; negatively in the sense that the failure of the HGP to deliver the promised social benefits was turned into a reason for yet more research, this time in proteomics, to fill this as-yet unmet need. 

As a route to new medicines and foods, proteomics has an advantage over genomics in that, because proteins comprise the structures and perform the vital functions of living organisms, they are much closer than DNA to where the biological action is. However, the complexity and massive yet unknown size of the proteome on the one hand, and the absence of adequate research platforms on the other, mean that despite advances in separations, mass spectrometry, bioinformatics and reference databases, proteomics is still not capable of the systematic identification of every single protein in a human cell.  

So what are the possible roles for proteomics in the post-HGP New Biology? Modelled on the HGP, the first generation of HUPO’s Pilot Project Initiatives focused on proteomics as a “discovery science” for cataloguing and profiling the proteomes of plasma, liver and brain. However, current platforms only capture the so-called “low hanging fruits” which constitute just a fraction of the protein types in a sample. This means that whilst protein biologists may feel they are drowning in a sea of data, systems biologists waiting at the end of the proteomics data pipeline are more likely to complain of thirst. Rather than a contradiction, this constitutive relationship illustrates how proteomics and e-science co-produce each other.

Moreover, maintaining a funding stream for “discovery science” research has proven problematic. Some public and charitable sponsors prefer to fund traditional, hypothesis-driven research proposals that address biological and biomedical questions and social problems. It is thus notable that the new generation of HUPO Initiatives have switched emphasis from protein-cataloguing to biomarker-discovery and applications, although not without some debate regarding the future direction of proteomics. Should it (funding permitting) prioritise technology-development towards the systems biology ideal of “full information” and risk delaying benefit-delivery? Or should it prioritise benefit-delivery and risk basing applications on just the “low hanging fruits”?  And if so, what are the implications for systems biology?  

Future Events: 
Interested in this topic? Then you may be interested in “New Biologies: Systems Biology and Proteomics - Is biology being re-shaped by genomics and its successors?” Session at the EGN Conference, London, 25-26 October 2007. For further details contact Session Co-Organiser: R.McNally@lancs.ac.uk (​mailto:McNallyR@cf.ac.uk​)
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